{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:24:39Z","timestamp":1780964679076,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T00:00:00Z","timestamp":1517270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Austrian Registry on Hypomethylating Agents - Arbeitsgemeinschaft Medikament\u00f6se Tumortherapie"},{"DOI":"10.13039\/501100011852","name":"Paracelsus Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011852","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00508-018-1315-2","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T10:39:20Z","timestamp":1517308760000},"page":"115-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Establishment and validation of a\u00a0novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia"],"prefix":"10.1007","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9184-4038","authenticated-orcid":false,"given":"Florian","family":"Huemer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Neureiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Egle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Voskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Zebisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Burgstaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Stauder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alois","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pfeilst\u00f6cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Machherndl-Spandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarete","family":"Stampfl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"key":"1315_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et\u00a0al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"1315_CR2","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ajh.23846","volume":"89","author":"EA Wassie","year":"2014","unstructured":"Wassie EA, Itzykson R, Lasho TL, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a\u00a0mayo clinic-French consortium study. Am J Hematol. 2014;89:1111\u20135.","journal-title":"Am J Hematol"},{"key":"1315_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s11899-015-0271-4","volume":"10","author":"KB McCullough","year":"2015","unstructured":"McCullough KB, Patnaik MM. Chronic myelomonocytic leukemia: a\u00a0genetic and clinical update. Curr Hematol Malig Rep. 2015;10:292\u2013302.","journal-title":"Curr Hematol Malig Rep"},{"key":"1315_CR4","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","volume":"121","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, Kosmider O, Renneville A, et\u00a0al. Clonal architecture of chronic myelomonocytic leukemias. Blood. 2013;121:2186\u201398.","journal-title":"Blood"},{"key":"1315_CR5","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, Galli A, Such E, et\u00a0al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128:1408\u201317.","journal-title":"Blood"},{"key":"1315_CR6","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood.V99.3.840","volume":"99","author":"F Onida","year":"2002","unstructured":"Onida F, Kantarjian HM, Smith TL, et\u00a0al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a\u00a0retrospective analysis of 213 patients. Blood. 2002;99:840\u20139.","journal-title":"Blood"},{"key":"1315_CR7","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1080\/10428190701216386","volume":"48","author":"M Beran","year":"2007","unstructured":"Beran M, Wen S, Shen Y, et\u00a0al. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson prognostic scoring system. Leuk Lymphoma. 2007;48:1150\u201360.","journal-title":"Leuk Lymphoma"},{"key":"1315_CR8","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","volume":"121","author":"E Such","year":"2013","unstructured":"Such E, Germing U, Malcovati L, et\u00a0al. Development and validation of a\u00a0prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121:3005\u201315.","journal-title":"Blood"},{"key":"1315_CR9","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/leu.2013.88","volume":"27","author":"MM Patnaik","year":"2013","unstructured":"Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27:1504\u201310.","journal-title":"Leukemia"},{"key":"1315_CR10","first-page":"52","volume":"6","author":"C Aul","year":"1992","unstructured":"Aul C, Gattermann N, Heyll A, et\u00a0al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia. 1992;6:52\u20139.","journal-title":"Leukemia"},{"key":"1315_CR11","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, et\u00a0al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079\u201388.","journal-title":"Blood"},{"key":"1315_CR12","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, et\u00a0al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"1315_CR13","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, Kosmider O, Renneville A, et\u00a0al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J\u00a0Clin Oncol. 2013;31:2428\u201336.","journal-title":"J Clin Oncol"},{"key":"1315_CR14","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/leu.2014.125","volume":"28","author":"MM Patnaik","year":"2014","unstructured":"Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a\u00a0two-center study of 466 patients. Leukemia. 2014;28:2206\u201312.","journal-title":"Leukemia"},{"key":"1315_CR15","volume-title":"Chronic myeloid neoplasias and clonal overlap syndromes","author":"L Pleyer","year":"2010","unstructured":"Pleyer L, Neureiter D, Faber V, Greil R. Chronic myeloid neoplasias and clonal overlap syndromes. Wien, New York: Springer; 2010."},{"key":"1315_CR16","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","volume":"88","author":"E Wattel","year":"1996","unstructured":"Wattel E, Guerci A, Hecquet B, et\u00a0al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des myelodysplasies and European CMML group. Blood. 1996;88:2480\u20137.","journal-title":"Blood"},{"key":"1315_CR17","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1002\/cncr.25759","volume":"117","author":"R Costa","year":"2011","unstructured":"Costa R, Abdulhaq H, Haq B, et\u00a0al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer. 2011;117:2690\u20136.","journal-title":"Cancer"},{"key":"1315_CR18","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/cncr.22457","volume":"109","author":"A Aribi","year":"2007","unstructured":"Aribi A, Borthakur G, Ravandi F, et\u00a0al. Activity of decitabine, a\u00a0hypomethylating agent, in chronic myelomonocytic leukemia. Cancer. 2007;109:713\u20137.","journal-title":"Cancer"},{"key":"1315_CR19","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL, et\u00a0al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a\u00a0study of the cancer and leukemia group B. J\u00a0Clin Oncol. 2002;20:2429\u201340.","journal-title":"J Clin Oncol"},{"key":"1315_CR20","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Issa JP, Rosenfeld CS, et\u00a0al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a\u00a0phase III randomized study. Cancer. 2006;106:1794\u2013803.","journal-title":"Cancer"},{"key":"1315_CR21","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1200\/JCO.1999.17.9.2819","volume":"17","author":"M Beran","year":"1999","unstructured":"Beran M, Estey E, O\u2019Brien S, et\u00a0al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J\u00a0Clin Oncol. 1999;17:2819\u201330.","journal-title":"J Clin Oncol"},{"key":"1315_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13576","author":"A Symeonidis","year":"2015","unstructured":"Symeonidis A, van Biezen A, de Wreede L, et\u00a0al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the chronic malignancies working party of the European group for blood and marrow transplantation. Br J Haematol. 2015; https:\/\/doi.org\/10.1111\/bjh.13576 .","journal-title":"Br J Haematol"},{"key":"1315_CR23","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3324\/haematol.2013.084020","volume":"98","author":"F Onida","year":"2013","unstructured":"Onida F, Barosi G, Leone G, et\u00a0al. Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups. Haematologica. 2013;98:1344\u201352.","journal-title":"Haematologica"},{"key":"1315_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.6004\/jnccn.2015.0038","volume":"13","author":"PL Greenberg","year":"2015","unstructured":"Greenberg PL, Stone RM, Bejar R, et\u00a0al. Myelodysplastic syndromes, version 2.2015. J\u00a0Natl Compr Canc Netw. 2015;13:261\u201372.","journal-title":"J Natl Compr Canc Netw"},{"key":"1315_CR25","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swederlow","year":"2008","unstructured":"Swederlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th\u00a0ed. Lyon: International Agency for Research on Cancer; 2008.","edition":"4"},{"key":"1315_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32\u20135.","journal-title":"Cancer"},{"key":"1315_CR27","unstructured":"National Cancer Institute NCI, NIH, DHHS. Common Terminology Criteria for Adverse Events v4.0. May 29, 2009 NIH publication # 09-7473."}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-018-1315-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-018-1315-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-018-1315-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T08:28:58Z","timestamp":1603700938000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-018-1315-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":27,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["1315"],"URL":"https:\/\/doi.org\/10.1007\/s00508-018-1315-2","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,30]]},"assertion":[{"value":"7 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"F.\u00a0Huemer received travel support from Roche and Merck. L.\u00a0Weiss reports receiving honoraria from Bayer, Ipsen, Lilly and Shire; travel support from Abbvie, BMS, Pfizer and Pharmamar; research funding from Takeda. A.\u00a0Egle is a\u00a0consultant for Celgene and reports receiving honoraria from Celgene. K.\u00a0Geissler has been a\u00a0member of advisory boards for Celgene. A.\u00a0Zebisch reports receiving honoraria from Celgene and Novartis. S.\u00a0Burgstaller has been a\u00a0consultant for Celgene and Novartis, a\u00a0member on the Board of Directors or advisory committees for Celgene and Novartis and reports receiving research funding from Celgene and honoraria from AOP Orphan Pharmaceuticals, Celgene, Mundipharma and Novartis. R.\u00a0Stauder has been a\u00a0consultant and a\u00a0member on the Board of Directors or advisory committees for Celgene and reports receiving research funding and honoraria from Celgene, Teva (Ratiopharm) and Novartis. W.R.\u00a0Sperr has been a\u00a0consultant for Celgene. Alois Lang has been a\u00a0consultant for Celgene. M.\u00a0Pfeilst\u00f6cker has been a\u00a0consultant for Celgene and Novartis and reports receiving honoraria from Celgene, Novartis and Janssen-Cilag. S.\u00a0Machherndl-Spandl has been a\u00a0member of an advisory board for Celgene. R.\u00a0Greil reports receiving honoraria from Bristol-Myers-Squibb, Cephalon, Amgen, Eisai, Mundipharma, Merck, Janssen-Cilag, Genentech, Novartis, AstraZeneca, Boehringer Ingelheim, Pfizer, Roche and Sanofi Aventis, research funding from Cephalon, Celgene, Amgen, Mundipharma, Genentech, Pfizer, GSK and Ratiopharm and has been a\u00a0consultant for Bristol-Myers-Squibb, Cephalon and Celgene. L.\u00a0Pleyer has been a\u00a0consultant for Agios, Celgene, Bristol-Myers Squibb and Novartis and reports receiving honoraria and travel support from Agios, Celgene, Bristol-Myers Squibb, Novartis and AOP Orphan Pharmaceuticals. V.\u00a0Faber, D.\u00a0Neureiter, D.\u00a0Voskova, A.\u00a0Pichler, M.\u00a0Stampfl declare that no competing interests exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective analysis was approved by the Ethics Committee of the provincial government of Salzburg, Austria (reference number 415-EP\/39\/11). All patients alive at the time point of data acquisition signed an informed consent to allow the collection of personal data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}